Labcorp: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Oct. 28, 2026, Labcorp (NYSE:LH) announced 7% revenue growth to $3.8 billion alongside raised full-year guidance. Enterprise profit expansion and solid organic demand show how scale keeps driving long-term earnings leverage. Three things management said stand out.

1. Medicare Price Cuts Pose a $125 Million Revenue Headwind

Proposed fee schedule changes under PAMA, the Protecting Access to Medicare Act, will lower Medicare reimbursement rates across hundreds of tests starting in 2027. Management plans to counter the $125 million hit through volume growth, biopharma demand, and cost efficiencies.

As we look toward 2027, based on the preliminary fee schedule proposed by CMS, we estimate the impact of PAMA to be approximately $125 million.
-- Julia Wang, Executive vice president and chief financial officer

2. Specialty Testing Acceleration Lifts Core Laboratory Volumes

High-growth specialty areas like oncology and neurology carry higher margins and pull routine volume along with them. Physicians ordering specialized diagnostic panels routinely send companion core testing to the same laboratory provider.

Our specialty testing business continues to grow about 3x faster than the broader diagnostics market. Importantly, this growth creates a halo effect for our core laboratory business as physicians often order specialty tests alongside other LabCorp tests for their patients.
-- Adam H. Schechter, Chairman and Chief Executive Officer

3. Tuck-In Acquisitions Expand Scale and Boost Future Margins

Agreements to buy assets from BioReference, Myriad Genetics' prenatal business, and Millennium Health target local market density. These acquisitions are expected to be accretive to adjusted EPS (earnings per share) in year one.

They are all tuck in nature, whereby we have a very strong track record of successfully integrating them into our extensive operating scale and infrastructure and then being able to really drive synergistic value through both growing the top line and also optimizing the cost structure.
-- Julia Wang, Executive vice president and chief financial officer

Looking Ahead

Operating efficiency and organic expansion continue to expand profitability, giving management the flexibility to absorb reimbursement regulatory shocks. Its global central laboratory footprint, proprietary specialty assay portfolio, and disciplined cost initiatives through Launchpad, its enterprise cost savings program, anchor long-term value creation. Management focuses on organic growth and pricing discipline to compound shareholder returns.

Q3 represented the sixth consecutive quarter of margin progression across the enterprise, inclusive of the 2 operating segments.
-- Julia Wang, Executive vice president and chief financial officer

Integrating newly acquired assets into the core network while maintaining book-to-bill strength across biopharma services provides clear operational momentum as regulatory policy shifts unfold.

We are confident in our strategy. We are encouraged by the opportunities ahead of us and we are well positioned for continued strong performance moving forward.
-- Adam H. Schechter, Chairman and Chief Executive Officer

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.